CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma

Journal of Gastrointestinal Cancer

Volumn 38, Issue 2-4, 2007, Pages 108-114

  Ali, Clinton W ^a,b   Kaye, Thomas F ^a   Adamson, Douglas J A ^a   Tait, Iain S ^a   Polignano, Francesco M ^a   Highley, Martin S ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

^b Flat 20 Caird House ^*  (United Kingdom)

Author keywords

CA 19 9 antigen; Cholangiocarcinoma; Pancreatic neoplasms

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; OXALIPLATIN; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; DRUG DERIVATIVE; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER PATIENT; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL PRACTICE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HUMAN; HYPERBILIRUBINEMIA; MALE; PANCREAS ADENOCARCINOMA; PANCREAS BIOPSY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; ADENOCARCINOMA; BILE DUCT TUMOR; BLOOD; CANCER STAGING; INTRAHEPATIC BILE DUCT; MIDDLE AGED; MORTALITY; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CA-19-9 ANTIGEN; CHOLANGIOCARCINOMA; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 60849127018     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-008-9019-x     Document Type: Article

References (21)

1. H Koprowski Z Steplewski K Mitchell M Herlyn D Herlyn P Fuhrer 1979 Colorectal carcinoma antigens detected by hybridoma antibodies Somat Cell Genet 5 957 971
2. MJ Duffy 1998 CA 19-9 as a marker for gastrointestinal cancers: a review Ann Clin Biochem 35 364 370
3. J Glenn WM Steinberg SH Kurtzman SM Steinberg WF Sindelar 1988 Evaluation of the utility of a radioimmunoassay for serum CA19-9 levels in patients before and after treatment of carcinoma of the pancreas J Clin Oncol 6 462 468
4. M Yasue J Sakamoto S Teramukai T Morimoto K Yasui N Kuno K Kurimoto Y Ohashi 1994 Prognostic values of preoperative and postoperative CEA and CA19.9 levels in pancreatic cancer Pancreas 9 735 740
5. W Steinberg 1990 The clinical utility of the CA 19-9 tumor-associated antigen Am J Gastroenterol 85 350 355
6. O Micke F Bruns R Kurowski E Horst AF deVries JW Hausler N Willich U Schäfer 2003 Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy Int J Radiat Oncol Biol Phys 57 90 97
7. U Halm T Schumann I Schiefke H Witzigmann J Mössner V Keim 2000 Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer Br J Cancer 82 1013 1016
8. ED Saad MC Machado D Wajsbrot R Abramoff PM Hoff J Tabacof A Katz SD Simon RC Gansl 2002 Pretreatment CA19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine Int J Gastrointest Cancer 32 35 41
9. C Ziske C Schlie M Gorschlüter A Glasmacher U Mey J Strehl T Sauerbruch IGH Schmidt-Wolf 2003 Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine Br J Cancer 89 1413 1417
10. AH Ko J Hwang AP Venook JL Abbruzzese EK Bergsland MA Tempero 2005 Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose gemcitabine for advanced pancreatic cancer Br J Cancer 93 195 199
11. ML Rothenberg JL Abbruzzese M Moore RK Portenoy JM Robertson HJ Wanebo 1996 A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma Cancer 78 627 632
12. CR Ferrone DM Finkelstein SP Thayer A Muzikansky C Fernandez-del Castillo AL Warshaw 2006 Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol 24 2897 2902
13. M Ikeda S Okada K Tokuuye H Ueno T Okusaka 2001 Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy Cancer 91 490 495 (Pubitemid 32105694)
14. Y Shibamoto T Manabe G Ohshio K Sasai Y Nishimura M Imamura M Takahashi M Abe 1996 High-dose intraoperative radiotherapy for unresectable pancreatic cancer Int J Radiation Oncology Biol Phys 34 57 63 (Pubitemid 26019954)
15. M Tempero H Takasaki HR Metzger P Pour 1989 Tumor antigen levels predict survival in pancreatic cancer Proc Am Soc Clin Oncol 8 113
16. NR Maisey AR Norman A Hill A Massey J Oates D Cunningham 2005 CA 19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials Br J Cancer 93 740 743
17. CMS Rocha-Lima D Savarese H Bruckner A Dudek J Eckardt J Hainsworth F Yunus E Lester W Miller W Saville GL Elfring PK Locker LD Compton LL Miller MR Green 2002 Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer J Clin Oncol 20 1182 1191
18. V Heinemann M-M Schermuly P Stieber L Schulz D Jüngst R Wilkowski A Schalhorn 1999 CA19-9: A predictor of response in pancreatic cancer treated with gemcitabine and cisplatin Anticancer Res 19 2433 2436
19. RA Abrams LB Grochow A Chakravarthy TA Sohn ML Zahurak TL Haulk S Ord RH Hruban KD Lillemoe HA Pitt JL Cameron CJ Yeo 1999 Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels Int J Radiat Oncol Biol Phys 44 1039 1046
20. S-H Kau Y-M Shyr C-H Su C-W Wu W-Y Lui 1999 Diagnostic and prognostic values of CA 19-9 and CEA in periampullary cancers J Am Coll Surg 188 415 420
21. C Haglund PJ Roberts P Kuusela TM Scheinin O Mäkelä H Jalanko 1986 Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer Br J Cancer 53 197 202 (Pubitemid 16095559)